| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 31, 2023 |
| Accession Number: | 0001193125-23-085637 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 31, 2023 |
| Accession Number: | 0001193125-23-085637 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
HC Wainwright reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Otonomy with a rating of Buy and set a new price target of $5.50 from $10.00 previously
Piper Sandler reiterated coverage of Otonomy with a rating of and set a new price target of $5.00 from $10.00 previously
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company's shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022. Following such suspension, the company's shares will be traded on the OTC Pink Market. As previously reported, on November 14, 2022, Otonomy received a notice from Nasdaq indicating that the Listing Qualifications Staff (the Staff) had determined to delist the company's securities unless the company timely requested a hearing before the Nasdaq Hearings Panel (the Pan
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC) today announced that the company's board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including the proceeds from the sale of any pipeline assets. To reduce cost, Otonomy has implemented a reduction in workforce. These updates are discussed below. Evaluation of Strategic Options As previously reported, Otonomy initiated an evaluation of strategic options to realize value from its pipeline. The
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities. Otonomy Program and Corporate Activity Updates In August 2022, Otonomy announced that OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints in a Phase 2 clinical trial in tinnitus patients. Based on these results, Otonomy discontinued development of OTO-313 and implemented other measures to extend its cash runway. Th
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
SC 13G/A - OTONOMY, INC. (0001493566) (Subject)
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment completed for higher dose evaluation with top-line results expected in fourth quarter of 2022OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biop
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022. A live webcast of the call will be available online in the investor relations section of Otonomy's website at www.otonomy.com and will be archived there for 30 days. To access the live call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minu
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected in August 2022; clinical safety evaluation of higher and bilateral dosing ongoingOTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023Current capital funds operations through multiple clinical readouts and into second half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today repor
3 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
4 - OTONOMY, INC. (0001493566) (Issuer)
Gainers Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday's pre-market session. The market value of their outstanding shares is at $13.0 million. DBV Technologies (NASDAQ:DBVT) shares moved upwards by 27.11% to $1.5. The company's market cap stands at $281.9 million. Humanigen (NASDAQ:HGEN) shares rose 18.09% to $0.12. The company's market cap stands at $14.1 million. Owlet (NYSE:OWLT) stock moved upwards by 13.28% to $0.82. The market value of their outstanding shares is at $93.8 million. NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 13.06% to $0.24. The company's market cap stands at $7.9 million. The company's, Q4 earnings came out 3 days ago. Personalis (NASD
Gainers Immuron (NASDAQ:IMRN) shares increased by 37.9% to $2.22 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 17.1 million shares, making up 288523.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million. Scopus BioPharma (NASDAQ:SCPS) shares increased by 25.0% to $0.1. As of 12:30 EST, this security is trading at a volume of 85.9K shares, making up 8.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million. DBV Technologies (NASDAQ:DBVT) shares moved upwards by 21.18% to $1.43. As of 12:30 EST, DBV Technologies's stock is trading
OnFriday, 143 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Tesla (NASDAQ:TSLA). The smallest company in terms of market cap to set a new 52-week low was Quotient (NASDAQ:QTNT). BIT Mining (NYSE:BTCM)'s stock dropped the most, trading down 774.92% to reach a new 52-week low. Harbor Custom Dev (NASDAQ:HCDI)'s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low. The following stocks set new 52-week lows on Friday: Tesla (NASDAQ:TSLA) shares hit a yearly low of $121.02. The stock was down 3.15% on the session. Rivian Automotive (NASDAQ:RIVN) shares reac
15-12G - OTONOMY, INC. (0001493566) (Filer)
EFFECT - OTONOMY, INC. (0001493566) (Filer)
EFFECT - OTONOMY, INC. (0001493566) (Filer)
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors. "Jill is an excellent addition to the board with strong strategic, operational and financial expertise within the biopharmaceutical sector," said David A. Weber, Ph.D., president and CEO of Otonomy. "We are excited to welcome her as we continue our growth trajectory and make progress to achieving our clinical milestones." Since 2018, Ms. Broadfoot has served as chief financial officer (CFO) of aTyr Pharma, Inc., a biotherapeutics company. P